Investigators charged that the company promoted the drug for conditions it was not approved to treat. The settlement also covers some cases in which Bristol allegedly inflated drug
prices, so government programs for the poor and elderly paid more.
The tentative agreement is one of the biggest in recent years for drug makers regarding drug marketing and pricing. It is subject to approval by the U.S. Department of Justice and was struck with Justice and the U.S. Attorney for the District of Massachusetts. Under the terms, no criminal charges will be filed against Bristol.
advertisement
advertisement